Intro to Ophthalmic NDDS - Eye Spy New Ways
- Ophthalmic NDDS: Advanced formulations/devices designed to optimize ocular drug delivery, overcoming limitations of traditional eye drops (e.g., rapid precorneal clearance).
- Importance: Essential for effective management of anterior/posterior segment diseases, improving therapeutic outcomes.
- Key Advantages:
- ↑ Bioavailability, sustained drug levels.
- ↓ Dosing frequency → ↑ patient adherence.
- Targeted delivery, minimizing off-target effects.
- Reduced systemic toxicity & local irritation.
- Core Challenges:
- Formidable ocular barriers (tear film, cornea, blood-ocular barriers).
- Drug stability, sterility, biocompatibility.
- Patient acceptance & cost-effectiveness.
⭐ Primary advantage: Enhanced bioavailability and reduced dosing frequency, leading to improved patient compliance and therapeutic efficacy.
Anterior Segment NDDS - Front Door Delivery
| Feature | Contact Lenses (CLs) | Ocular Inserts (e.g., Ocusert) | Punctal Plugs | In-situ Gels |
|---|---|---|---|---|
| Form | Drug-eluting; soft/rigid | Solid, polymeric; erodible/non | Biocompatible; occludes puncta | Liquid → gel (pH, temp, ion trigger) |
| Mechanism | ↑ Contact time, sustained release | Cul-de-sac placement; prolonged use | Blocks tear drainage; ↑ drug retention | ↑ Viscosity, ↑ precorneal residence time |
| Pros | ↑ Bioavailability, convenience | Zero-order release, ↓ dosing freq. | Minimally invasive, targeted | Easy application, ↑ contact time |
| Cons | Lens issues, limited drug capacity | Foreign body sensation, expulsion | Expulsion, irritation | Initial blur, variable gelation |
| Examples | Glaucoma, dry eye, antibiotic CLs | Pilocarpine (Ocusert), Lacrisert | Dexamethasone insert, glaucoma plugs | Timolol, Moxifloxacin gels |
Posterior Segment NDDS - Backstage Pass Drugs
- Key approaches to overcome barriers for drug delivery to retina/choroid.
| System | Delivery & Duration | Pros | Cons | Examples |
|---|---|---|---|---|
| Intravitreal Inj. | Direct bolus; Weeks-Months | Rapid onset, High local conc. | Repeated, Endophthalmitis risk, IOP ↑ | Anti-VEGFs (Ranibizumab, Aflibercept) |
| Implants (Bio) | Sustained release, degrades; Months | No removal needed, Predictable release | Initial burst, Inflammation | Ozurdex (Dexamethasone 0.7 mg) |
| Implants (Non-Bio) | Sustained release, needs removal; Months-Years | Longest duration, Stable release | Surgical removal, Fibrosis risk | Retisert, Iluvien (Fluocinolone acetonide) |
| Particulate Systems | Targeted, sustained release; Variable (Days-Months) | ↑Bioavailability, ↓Toxicity, Cross barriers | Complex manufacturing, Stability issues | Liposomes (Verteporfin), Nanoparticles |
Emerging Ophthalmic NDDS - Eye‑Tech Horizons
- Gene Therapy: Viral (AAV) & non-viral vectors for sustained intraocular drug production (e.g., anti-VEGF). Targets retinal dystrophies, AMD.
- Cell-Based Delivery: Encapsulated Cell Technology (ECT) for continuous, long-term protein delivery.
- Stimuli-Responsive Systems:
- Smart Hydrogels: Drug release triggered by pH, temperature, light.
- Nanocarriers: Nanoparticles, liposomes for targeted delivery, enhanced penetration.
- Iontophoresis: Non-invasive transcorneal/transscleral drug delivery via electric current.
- Microneedles: Minimally invasive arrays for precise suprachoroidal/intrascleral drug placement.
⭐ Microneedles enable minimally invasive suprachoroidal or intrascleral drug delivery, enhancing local efficacy and reducing systemic exposure.
High‑Yield Points - ⚡ Biggest Takeaways
- Novel drug delivery systems (NDDS) enhance ocular bioavailability, prolong drug action, and improve patient compliance.
- Examples: liposomes, nanoparticles, hydrogels, microneedles, and ocular inserts (e.g., Lacrisert).
- Drug-eluting contact lenses provide continuous topical medication release.
- Intravitreal implants (e.g., Retisert, Ozurdex) offer long-term therapy for posterior segment diseases.
- Biodegradable polymers (e.g., PLGA) and non-biodegradable systems ensure sustained drug release.
- Key challenges: overcoming ocular barriers (cornea, BRB) and rapid tear turnover.
- Benefits include reduced dosing frequency and minimized systemic side effects.
Unlock the full lesson and continue reading
Signup to continue reading this lesson and unlimited access questions, flashcards, AI notes, and more
